Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Oryzon Genomics S.a.

Clinical trials sponsored by Oryzon Genomics S.a., explained in plain language.

Oryzon Genomics S.A. ORY BME

A Spanish biopharmaceutical company developing epigenetic therapies for cancer and neurological diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

New pill aims to calm borderline personality disorder symptoms

Symptom relief Completed

This study tested an experimental drug called vafidemstat in 211 adults with borderline personality disorder (BPD) to see if it could reduce agitation and aggression. Participants took either the drug or a placebo for 14 weeks. The goal was to measure changes in symptom severity …

Phase: PHASE2 • Sponsor: Oryzon Genomics S.A. • Aim: Symptom relief

Last updated Jun 27, 2026 12:29 UTC